Novo Nordisk announced on September 29, 2026 that it will pay up to $2.6 billion — $300 million of it upfront — to license HRS-1596, a preclinical once-weekly oral GLP-1/GIP dual receptor agonist, from China's Jiangsu Hengrui Pharmaceuticals. Novo gets exclusive rights to develop, manufacture and commercialize the drug everywhere except the Chinese mainland, Hong Kong, Macao and Taiwan.
The headline number is not the interesting part. The mechanism is. GLP-1/GIP dual agonism is the pharmacology behind tirzepatide — Eli Lilly's compound, and the one Novo's semaglutide has been losing head-to-head efficacy comparisons to for three years. Novo just paid nine figures upfront for a molecule that has never been dosed in a human, built on its rival's mechanism, from a Chinese licensor whose sister compound is already through phase 3 in China.
Research-context information only. Compounds discussed below are research peptides, investigational drugs, or approved pharmaceuticals depending on the molecule; several are not approved by the FDA. Protocols, doses, and outcomes reported come from published research and company disclosures. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
HRS-1596 itself has never been available outside Hengrui's development program and cannot be sourced anywhere.
The Deal
The structure, per the joint announcements from Novo and Hengrui:
- $300 million upfront, with development, regulatory and commercial milestones taking the potential total to $2.6 billion
- Ex-Greater-China rights to Novo; Hengrui keeps the Chinese mainland, Hong Kong, Macao and Taiwan
- Stage: phase-1-ready. Hengrui has received approval in China to begin phase 1 trials in weight management and type 2 diabetes, but no human has received the drug yet
HRS-1596 is designed to reduce weight and improve glycemic control through the now-familiar dual route: appetite suppression via GLP-1 receptor agonism plus insulin secretion and insulin-sensitivity effects via GIP receptor agonism. Novo's chief scientific officer said the company is "excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field."
That word — convenience — is doing a lot of work. The approved oral GLP-1 options are daily: oral semaglutide is a daily peptide tablet dependent on an absorption-enhancer formulation, and orforglipron is a daily small molecule. Viking's leading oral candidate is daily. A genuinely once-weekly oral in this class would be a first, and it is worth flagging plainly that once-weekly oral dosing is a design goal from preclinical data, not a demonstrated property in humans. Plenty of oral-dosing claims in this class have not survived contact with phase 1 pharmacokinetics.
Why Novo Wants Tirzepatide's Mechanism
Novo built its obesity franchise on GLP-1 alone (semaglutide), and its next-generation bets on GLP-1 plus amylin: the semaglutide/cagrilintide combination, which posted roughly 20% weight loss in its REDEFINE phase 3 program and is now under FDA review, and amycretin, a single molecule hitting GLP-1 and amylin receptors, now in phase 3. What Novo conspicuously did not have was a GIP agonist — the mechanism that keeps winning the efficacy tables.
| Compound | Mechanism | Modality | Status |
|---|---|---|---|
| Semaglutide (Novo) | GLP-1 | weekly injection / daily oral | approved |
| Tirzepatide (Lilly) | GLP-1 + GIP | weekly injection | approved, ~21-22% weight loss |
| Retatrutide (Lilly) | GLP-1 + GIP + glucagon | weekly injection | phase 3 complete, 28-30% weight loss, filing expected Q1 2027 |
| HRS9531 / KAI-9531 (Hengrui/Kailera) | GLP-1 + GIP | weekly injection | phase 3 positive in China |
| HRS-1596 (Hengrui/Novo) | GLP-1 + GIP | once-weekly oral (goal) | preclinical, phase-1-ready |
Two things stand out in that table. First, every compound above semaglutide on the efficacy ladder activates the GIP receptor. Lilly's tirzepatide posted ~21% mean weight reduction at 72 weeks in SURMOUNT-1, and retatrutide's TRIUMPH program has now delivered 28-30% across its phase 3 readouts. Novo has watched that gap from the GLP-1-plus-amylin side of the fence. This deal is the company hedging its own thesis.
Second, Hengrui is not a random licensor. Its injectable GLP-1/GIP dual agonist HRS9531 went through positive phase 3 trials in China and is being developed for the rest of the world as KAI-9531 by Kailera Therapeutics, which licensed four Hengrui metabolic assets in 2024 and rode them to one of the largest biotech IPOs of the cycle. Merck took Hengrui's oral Lp(a) inhibitor in May 2025. Novo is the third large-cap buyer at this particular window, and it paid a premium to get the oral follow-on molecule rather than the injectable that was already spoken for.
What This Means for Buyers
Nothing changes on any timescale that matters for sourcing, and the reasons are worth being precise about.
HRS-1596 was never sourceable and will not become sourceable. It is a proprietary molecule that has not entered human trials. It does not appear in research vendor catalogs, it is not on any compounding bulk-substance list, and no gray-market version exists. A preclinical license adds a future option to Novo's pipeline; it puts nothing on any shelf.
The timeline is early-2030s at best. Phase-1-ready means first-in-human dosing is still ahead. Six to eight years from that point to approval is the optimistic path, and preclinical assets fail at higher rates than any other stage. For perspective: retatrutide — with completed phase 3 trials and 28-30% weight loss in hand — will not reach pharmacies before late 2027 at the earliest.
The compounds actually available for research use today are unchanged. The GLP-1-class molecules vendors stock — semaglutide, tirzepatide, retatrutide, cagrilintide — are the same ones that were available yesterday, at the same per-milligram prices. Current vendor pricing is on the retatrutide, tirzepatide and semaglutide comparison pages, and active discount codes across recommended vendors are collected on the deals page.
If anything, the deal is a signal about where the field's center of gravity sits: the mechanisms drawing nine-figure upfront payments are the ones already represented in the research market. GIP-receptor dual agonism stopped being an experimental thesis some time ago — it is now the thing the market leader in GLP-1 pays $2.6 billion to catch up on.
